Fenu S., Cauli O., M., Morelli (2000) Cross-sensitization between the motor activating effects of bromocriptine and caffeine: role of adenosine A_2A receptors. Behav. Brain Res., 114, 97-105.

 

Pinna A., Fenu S., M., Morelli (2001) Motor stimulants effects of the adenosine A_2A receptor antagonist SCH 58261 do not developed tolerance after repeated treatments in 6-hydroxydopamine lesioned rats. Synapse, 39, 233-239

 

Morelli M., Pinna A. (2001) Modulation by adenosine A_2A receptors of dopamine-mediated motor behavior as a basis for antiparkinson's disease drugs. Drug Dev. Res. 52, 387-393.

 

Morelli M.,  Wardas J. (2001) Adenosine A_2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson’s disease. Neurotoxicity Res. 3, 545-556.

 

Pinna A, Morelli M (2001) Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci. Feb;22(1):71-2.

 

Carta A, Fenu S, Morelli M. (2001) Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease. Neurol Sci. Feb;22(1):59-60.
 

Carta A., Pinna A., Cauli O., M., Morelli (2002) Differential regulation of GAD67, enkephalin and dynorphin mRNA by chronic-intermittent L-dopa and A_2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 44 (3), 166-174.

 

Morelli M., Acquas E., E., Ongini  (2002) Dopamine-Adenosine interactions. In: Handbook of Exp. Pharacol. Vol. 154/II Dopamine in the CNS Ed. G. Di Chiara Sprinter-Verlag Berlin.

 

Pinna A., Corsi C., Carta A.R., Valentini V., Pedata F. and M. Morelli (2002) Modification of adenosine extracellular levels and adenosine A_2A receptor mRNA by dopamine denervation. Eur. J. Pharmacol. 446 (1-3), 75-82.

Cauli O, and M. Morelli (2002) Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. Psychopharmacology 162 (3) : 246-54.

 

Vorobyov VV, Schibaev NV, Morelli M, Carta AR. (2003) EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.  Brain Res. 972/1-2 pp 177 – 185.

 

Cocco MT, Congiu C, Onnis V, Morelli M, Cauli O (2003) Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur. J. Medic. Chemistry 38, 513-518.

 

Corsi C, Pinna A, Gianfriddo M, Melani A, Morelli M, Pedata F. (2003) Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur J Pharmacol. 7;464(1):33-8.

 

Cauli O, Pinna A, Valentini V and Morelli M (2003) Subchronic Caffeine Exposure Induces Sensitization to Caffeine and Cross-Sensitization to Amphetamine Ipsilateral Turning Behavior Independent from Dopamine Release.  Neuropsychopharm. 28 (10):1752-9.

 

Morelli M (2003) Adenosine A_2A antagonists: potential preventive and palliative treatment for Parkinson's disease. Exp. Neurology 184 (1):20-23.

 

Carta AR, Fenu S, Pala P, Tronci E and M. Morelli (2003) Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine lesioned rats. E. J. Neurosci. 18: 2563-2572.

 

Carta AR., A. Pinna, E. Tronci and M. Morelli (2003) Adenosine A_2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology  61: S39-43.

 

Carta AR., MA. Tabrizi, PG. Baraldi, A. Pinna, P. Pala, M. Morelli (2003) Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Exp. Neurology 184: 679-687.